Day 1: Thursday, 25 April 2024 (09:00-17:30)
09.00-09.45: Welcome
- Federal Minister of Social Affairs, Health, Care and Consumer Protection Johannes Rauch
- Executive Director Herwig Ostermann, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute)
- WHO Representative Klara Tisocki, Team Lead Health Technology Access Management team (AMP), Department of Innovation and Emerging Technologies (IET), Medicines and Health Products, World Health Organization Geneva
- European Commission (DG SANTE) representative, Rainer Becker, Director SANTE D – Medical Products and Innovation (video message)
- Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Sabine Vogler (GÖG / Austrian National Public Health Institute)
Facilitator: Nina Zimmermann, GÖG / Austrian National Public Health Institute
9.45-10.30: Keynote presentation: How to make medicines more accessible and affordable - From evidence to policy to practice
Meindert Boysen, Independent Consultant and Chair of Health Technology Assessment international (HTAi) Global Policy Forum, UK
Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute
10.30-11.00: Coffee Break
11.00-12.15: Stakeholder Debate: Ensuring access to affordable medicines through innovative policies?
- Johan Ponten, Dental and Pharmaceutical Benefits Agency (TLV), Sweden
- Thomas Allvin, European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Maja Graf, International Generic and Biosimilar Medicines Association (IGBA)
- Giulia Segafredo, Medicines Patent Pool
- Anca Toma, European Patients Forum
Facilitator: Dimitra Panteli, European Observatory on Health Systems and Policies, Belgium
12.15–12.30: Outlook on Conference
Nina Zimmermann, GÖG / Austrian National Public Health Institute
12.30-14.00: Lunch Break
14.00-14:20: Keynote presentation: Can people afford to pay for health care? Evidence on financial protection in 40 countries in Europe
Tamás Evetovits, WHO Barcelona Office for Health Systems Financing, Division of Country Health Policies and Systems
Facilitator: Nina Zimmermann, GÖG / Austrian National Public Health Institute
14.30–15.30: Breakout Session (Strand I – Strand III)
Strand I: Local challenges, global learnings?
Keynote presentation: Competition enforcement in the pharmaceutical sector - European competition authorities working together for affordable and innovative medicines download presentation
Leen De Vreese, European Commission, DG Competition, Belgium
- Are competition fines effective deterrents to excessive pricing of medicines? Evidence from a landmark competition case in the United Kingdom download presentation
Melissa Barber, Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), USA - Assessing medicines access time: a cross-country comparison in Europe download presentation
Sophie Delcroix-Lopes & Nadia Amer, National Health Insurance (CNAM), France
Facilitator: Veronika Wirtz, WHO Collaborating Center in Pharmaceutical Policy, Boston University School of Public Health, USA
Strand II: Strengthening the evidence base
Keynote presentation: Update from the WHO Fair Pricing Forum download presentation
Klara Tisocki, WHO Geneva, Switzerland
- Savings and Transparency: Comparing Publicly Reported Data on Managed Entry Agreements in Europe
Nora Franzen, Netherlands Cancer Institute, The Netherlands - Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies download presentation
Vittoria Ardito, Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Italy
Facilitator: Aukje Mantel-Teeuwisse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Netherlands
Strand III: Futureproofing pharmaceutical policies
Keynote presentation: Use of strategic approaches in public procurement of medicines: improving affordable patient access to medicines and protecting the environment in 32 European countries download presentation
Maximilian Salcher-Konrad, GÖG / Austrian National Public Health Institute
- Tendering of medically equivalent, patented outpatient pharmaceuticals download presentation
Hallstein Husbyn, Norwegian Medical Products Agency, Norway - First Nordic Tender with Environmental Criteria download presentation
Rasmus Syberg Hazelton, Amgros I/S, Denmark
Facilitator: Jaime Espin Balbino, Andalusian School of Public Health, Granada, Spain
15.30–16.00: Poster walk during the coffee break
16.00 –16.45: Moderated poster session
Strand I: Local challenges, global learnings?
- Early and compassionate access to medicines in France: two years after launch, what did and did not work? download poster
Newfel Chekroun & Mayeul Charoy, Direction de la sécurité sociale, France - Selection of novel medicines for acute conditions versus chronic conditions on National Essential Medicines Lists compared to the WHO Model List download poster
Moska Hellamand, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands - Bridging perspectives: identification of best practices for public and patient involvement in pharmaceutical pricing and reimbursement policies – a comprehensive study download poster
Lourdes Cantarero Arevalo, WHO Collaborating Centre in Patient Perspective on Medicine Use, Department of Pharmacy, University of Copenhagen, Denmark
Facilitator: Friederike Windisch, GÖG / Austrian National Public Health Institute
Strand II: Strengthening the evidence base
- Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’ download poster
Nicole Grössmann-Waniek, HTA Austria - Austrian Institute for Health Technology Assessment GmbH, Austria - Needs Examination, Evaluation and Dissemination (NEED): Towards a needs assessment framework and evidence database to support needs-driven innovation and policy in healthcare download poster
Muriel Levy, Belgian Health Care Knowledge Centre (KCE), Belgium - How to Price Advanced Therapies? Mixed approach for valuing a new CAR-T Cell for Multiple Myeloma in Brazil download poster
Augusto Guerra, Collaborating Centre for Health Technology Assessment and Excellence (CCATES) / Postgraduate Program in Medicines and Pharmaceutical Assistance at the Federal University of Minas Gerais (PPGMAF/UFMG), Belo Horizonte, Brazil
Facilitator: Margit Gombocz, GÖG / Austrian National Public Health Institute
Strand III: Futureproofing pharmaceutical policies
- Break on through (to the other side). A case study on increasing access to affordable CAR-T therapy through an academic hospital’s alternative innovation model download poster
Adrian Alonso Ruiz, Global Health Centre, Graduate Institute of Development and International Studies, Switzerland - Cost analysis of TB-PRACTECAL, a multicentre phase 2/3 trial in drug-resistant TB download poster
Melissa Barber, Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), USA - Using futures methods to think through financing for medicines R&D and issues of access download poster
Sarah Parkinson, RAND Europe, UK
Facilitator: Fatima Suleman, WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal, South Africa
16.45-17.30: Reception
Day 2: Friday 26 April 2024 (09:00 - 16:00)
08.00-08.45: Early Bird Session: Meet the Editors
- Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar download presentation
- International Journal of Technology Assessment in Health Care, Claudia Wild download presentation
- Health Policy Journal, Nathan Shuftan download presentation
- Adis HEOR Journals (Applied Health Economics and Health Policy, Pharmacoeconomics, Pharmacoeconomics - Open), Tim Wrightson (video message)
Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute
9.00-09.30: Keynote presentation: WHO and Access to medicines - an update
Natasha Azzopardi Muscat, WHO Regional Office for Europe, Denmark (video message)
Tarang Sharma, WHO Regional Office for Europe, Denmark (online) download presentation
Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute
9.30-10.30: Country poster presentations
European Union
- Croatia (Eva Šintić, Agency for Medicinal Products and Medical Devices of Croatia, Halmed and Martina Kavur Majer, Croatian Health Insurance Fund) download poster
- Denmark (Diana Ina Lauritzen, Danish Medicines Agency and Rasmus Syberg Hazelton, Amgros I/S) download presentation
- France (Mayeul Charoy, Direction de la sécurité sociale and Clement Huiban, CEPS, France) download poster
Facilitator: François Janssens, European Commission DG SANTE
Other European Countries
- Norway (Carolin Hagen, Norwegian Ministry of Health and Care Services) download poster
- Türkiye (Irem Karaomerlioglu, Turkish Medicines and Medical Devices Agency) download poster
- Ukraine (Oresta Piniazhko, State Expert Centre of Ministry of Health of Ukraine and Svitlana Pakhnutova, WHO Country Office Ukraine) download presentation
Facilitator: Iuliana Garam, WHO Country Office Moldova
Non-European Countries
- Brazil (Luciene Fontes Schluckebier Bonan, Brazilian Ministry of Health and Fernando Rego, ANVISA) download poster
- Singapore (Ivan Koh, Agency for Care Effectiveness (ACE), Ministry of Health) download poster
- South Africa (Andy Gray and Fatima Suleman, WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal) download presentation
Facilitator: Veronika Wirtz, WHO Collaborating Center in Pharmaceutical Policy,
Boston University School of Public Health, USA
10.30–11.00: Country Poster walk during the coffee break
11.00–12.30: Breakout Session (Strand I – III)
Strand I: Local challenges, global learnings?
Keynote presentation: Conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs) download presentation
Zaheer-Ud-Din Babar, Professor in Medicines and Healthcare, University of Huddersfield, UK
- Finland as a trailblazer in the uptake of less expensive biologic medicines – measures introduced in 2023 and 2024 download presentation
Kati Sarnola, Research at Kela, Social Insurance Institution of Finland (Kela), Finland - Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa download presentation
Iris Joosse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands - Human normal immunoglobulin in Portugal: Analysing price increases across multiple markets download presentation
Ana Correia, INFARMED – National Authority of Medicines and Health Products, I.P., Portugal
Facilitator: Aukje Mantel-Teeuwisse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Netherlands
Strand II: Strengthening the evidence base
Keynote presentation: The role of transparency and evidence in improving access to medicines download presentation
Dimitra Panteli, European Observatory on Health Systems and Policies, Belgium
- The desirability of implementing an outcome-based delayed payment model for autologous gene therapy atidarsagene autotemcel (Libmeldy®) download presentation
Marcelien Callenbach, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands - European comparison of prices for off-patent medicines – findings for 16 countries and implications for methodological choices download presentation
Peter Schneider, GÖG / Austrian National Public Health Institute
Facilitator: Jaime Espin Balbino, Andalusian School of Public Health, Granada, Spain
Strand III: Futureproofing pharmaceutical policies
Keynote presentation: OECD’s quest for transparency in pharma markets - an update on recent contributions download presentation
Eliana Barrenho, OECD, France
- Using AIM’s Fair Pricing Calculator for affordable and evidence-based pricing decisions, transitioning from policy concept to (inter-) national testing download presentation
Thomas Kanga-Tona, International Association of Mutual Benefit Societies (AIM), Belgium - Disaggregation Of The Costs Of Pharmaceutical Research And Development download presentation
Daniel Fabian, HTA Austria - Austrian Institute of Health Technology Assessment GmbH, Austria - Unlocking global access to medicines for pandemics: the potential and limits of alternative innovation models download presentation
Iulia Slovenski, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland
Facilitator: Fatima Suleman, WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, University of KwaZulu-Natal, South Africa
12.30–13.30: Lunch
13.30-15.00: Workshops
- Access to new and expensive medicines in Austria: what role for the new "appraisal board"?
A workshop organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, GÖG (Austrian National Public Health Institute) download presentation
Facilitator: Maximilian Salcher-Konrad (GÖG / Austrian National Public Health Institute)- Presentation of the Austrian pharmaceutical system (Sabine Vogler, GÖG / Austrian National Public Health Institute)
- Panel discussion on "Key challenges for affordable access to new medicines: what role for a new process for assessing selected new and expensive medicines in Austria?"
- Sarah Mörtenhuber (Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection)
- Claas Röhl (patient representative: NF Kinder)
- Nathanael Paterno (hospital payer: WIGEV / Vienna Healthcare Group)
- Ronald Pichler (pharmaceutical industry: PHARMIG)
- Invited commentary: Carolin Hagen (Norwegian Ministry of Health and Care Services)
- How the Euripid collaboration contributes to improving access to biosimilars
A workshop organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, GÖG (Austrian National Public Health Institute) and the EURIPID collaboration download presentation
Facilitator: Claudia Habl (GÖG / Austrian National Public Health Institute, Secretary of the Board of Participants (BoP) of EURIPID)- Introduction of EURIPID and current EC Grant (Gergely Németh, Semmelweis University, Hungarian National Health Insurance Fund, project manger of EURIPID)
- Impact of market entries of biosimilars in Slovenia (Matjaž Marc, Agency for Medicinal Products and Medical Devices of the Slovenian Republic (JAZMP))
- Panel discussion on „Biosimilars – Monitoring & policies in the product life cycle management“
- Francis Arickx (National Institute for Health and Disability Insurance (RIZIV-INAMI), Belgium) [online]
- Liese Barbier (Katholieke Universiteit Leuven, Belgium, European Medicines Agency (EMA))
- Dorthe Barthels (AMGROS I/S, Denmark)
- Frode Hellesnes (Biogen, Sweden)
- Cross-border HTA partnerships and their role in sustainable access to medicines
A workshop organised by the Deloitte Health Economics and Outcomes Research Team Brussels download presentation
Facilitator: Burcak Aydin, Health Economics and Outcomes Research Team Brussels Deloitte- Presentation on the cross-border HTA collaborations including methodology development, information sharing during an appraisal and a joint production of REAs
- Panel discussion on recent case studies where the cross-border HTA collaboration served to improve sustainable access to medicines (eg. reduction in appraisal timelines, higher quality appraisals) and what needs to be done more in the near future
- Dalia Dawoud (Associate Director, Science, Policy and Research Programme, National Institute for Health and Care Excellence (NICE), UK)
- Matteo Scarabelli (Associate Director, Market Access, EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium)
- Anja Schiel (Senior Advisor, Norwegian Medical Products Agency, Norway)
- Anca Toma (Executive Director, European Patients' Forum, Belgium)
15.00-15.45: Keynote presentation: Action needed: Rediscovering Solidarity in Europe and beyond
Anja Schiel, Senior Advisor, Norwegian Medical Products Agency, Norway download presentation
Facilitator: Sabine Vogler, GÖG / Austrian National Public Health Institute
15.45-16.00: Conclusions, awards and closure
Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, GÖG / Austrian National Public Health Institute